VNRX - Earnings call transcript Q3 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen and thank you for standing by. Welcome to the VolitionRx Limited's Third Quarter 2019 Earnings Conference Call.

During today’s presentation, all parties will be in a listen-only mode.

Following the presentation, the conference call will be opened for questions. [Operator Instructions] This conference is being recorded today, November 13, 2019.

turn of over Investor to Executive Scott like President Vice Relations. now the to call Powell, I'd Please go ahead.

Scott Powell

cover operating Thank XXXX you, ended of VolitionRx will our for earnings September conference financial and welcome with and everyone Limited. to XX, XXXX recent This a third activities for milestones. the results today's along call VolitionRx's quarter and discussion call upcoming key

we a remarks, prepared will question-and-answer our conference to open Following call session. the

Executive Cameron on Mr. Officer, call Chief are President Also Officer. and Mr. Benston, Reynolds, Financial our Chief David and today

well Before that Safe we include discussed conference remind of the as begin forward-looking as I'd available uncertainties like views involve These beliefs, Litigation our and provisions assumptions information have will concerning Harbor some on statements based reflect on based to us. future everyone Securities call the are to information of our used Act Private the under of currently risks, assumptions. statements these upon Because statements current these covered Reform this we XXXX. events, statements

or vary results future actual the by of number that factors to future on achievements a statements. significantly cause Actual or or expressed performance materially these different may events results, be from results based implied may

undertake course our during factors obligation with made risk not various call. XX-K identified have to We Annual statements our most operations update this forward-looking the Report other with any associated Commission. the do Exchange We in filings recent any and Form on of Securities and

call Officer, Mr. Cameron I'd over our Executive to Chief Reynolds. now to like turn President the Cameron? and

Cameron Reynolds

Vet. many cancer Asian and our with say for have call colorectal in platform Capture, Nu.Q we momentum development great course trials, happy fronts and everyone I'm year conference to Volition’s joining lung with of our you this Thank made and work, progress on Nu.Q have today.

DNA in tremendous start XXXX, and companies, was great our have technology. reiterating for been by range the Billions several us let well-known excited in space. groups, sequencing been have what treatment drug Firstly, makes and our there sequencing genome published mutations have strides and our made wide spent progress a in advances research so vision by Since and been of me with selection. human dollars of cancer

realization now one of is cells sequence to part does and be in of picture appears DNA DNA to useful cancer chromosomes a in unlikely, it exists for growing many and in there for DNA that nucleosomes. detection the the but isolation, made However, cancers. only be clinically in up not occur early example, as proteins is

we all all forms proteins. recipe essentially human recipe like DNA book recipe the But every making every for The books, don't day. make

are recipes chromosomes. epigenetic Some caused are are the cancer, chromosomal never advancing others are the normal and including same the epigenetics diseases, made and when a human epigenetics are VolitionRx Many protein loss by type of advances science these is DNA rarely, The company, human of recipes made. which by some health. regulations. an in dishes epigenetics determined exploring of on focused the just made and is often

with our fruition mission platform heart epigenetics. to Nu.Q of has founding, and since our the it's This at been our coming very

VolitionRx expanding is decade the it's player the IP in field. with we important full believe the position VolitionRx strong more, ever in portfolio chromosome. our it's strongly as, So extremely in the key a epigenetics DNA. team not work epigenetics, In say, expansive an the if this last be short, DNA, than our with at to We genetics, significant not of puts

making progress our with and I'm momentum have. excited Overall we by we I'm the are delighted

in years assays monoclonal We implausible ago that with calibrants, final a using routine to years many just something our have the spent was two great including grade a improvements now as recombinant assays. deal effort last over and few our antibodies of nucleosomes and product is developing

have of nature two we and platform. and have in studies across utilized confirm separate [ph] the the five today, they eight assays on cancers well manipulate, discovery simplest can reproducibility cohorts demonstrating our As robust its Nu.Q finalized performed of in now all to-date,

delighted our and traditional that to be announce in finalized play the now our with can some trials. assays kit that CE are And clinical both so, Marking [ph], of I'm IBD so regards our of to in we used process human then animal

large platforms world, platforms. in used In chemiluminescence magnetic based on around by very accessible a cetera, have all such the platforms format as work our ELISA on open parallel, range basic to leading also the global well undertaken smaller et the is which platform. we are tests a and diagnostic are beads, These automated as order as Abbott, broader of which Roche, companies, on also ensure are

we To recently expedite platforms believe transfer we the years delighted lab on clinical outside are work Europe to this, be platforms China. announce team. validation from in project XX our Indeed both has industry [indiscernible] expert has joined a these and to automotive operating than the with This us the AutoAnalyzer assay on allowed we that cutting first experience are more edge Belgium AutoAnalyzer to China.

adaptation our up platforms on also of and that a more be magnetic automation Not market, our beads increased can the the number on assays operated only platforms significantly of perhaps of factor has based importantly, accuracy more technology than by tenfold. but even ELISA and analytical this to in chemiluminescence the has a opened

cancer based large the these trial as We will our now assays Taiwan. scale utilize our program lung including and studies such collected in in clinical colorectal clinical studies bead

I first samples the processing kit of processed is will year. also and yet our yet that from contract published nuclear announce from progress and from to am we another service were kits. be promising the our research under that next our This only in samples with we our The contract results received have sales delighted momentum business. first again, area revenues research both

long versus enrich short quarter, This nucleosomes. nucleosomes be and used this development to ways. significant therefore milestone ability in a to Capture separating in Nu.Q The were tumor we Also could DNA breakthough delighted a number of by origin of from announce our program. non-tumor

by targets biomarker Firstly, be spectrometry, using mass may new discovered.

the sequence from in the an liquid nucleosomes as importantly, enriching origin by based biopsies technology, blood. cancer and enabling of Secondly,

VolitionRx's And increase gap this specificity epigenetics. sequencing in extremely between the lastly, in to the leader selection. epigenetic moving results, bridge highlight I assays profiling limited so VolitionRx signal. am field by impact treatment technology VolitionRx's enabling approach approaches sector the that as of that far to early been excited the to background and could could and personalized have These a recent clinical the detection entire

months, discrimination nucleosomes to developmental the determine a be analysis complete and using to sequencing of achievement will and The underway to work of is next reporting level immunoassays our step derive Nu.Q we which Capsure the in nucleosomes. coming in provide [indiscernible] is

while Belgium cash their keeping efforts. prior burn R&D team right team all quarters. consistent must continuing to go and with our remarkable and has low for Overall, Michel progress the Dr. Thanks our made Gaetan

all million cash the of of We and And closed versus the at last this cash third the equivalents so, to year. financials quarter $XX.X million $XX.X out important quarter. year-end in XXXX with

$XX.X very existing cash of During showing quarter, shares the shareholders common third our upon million to exercise warrants shareholder to by warrants support. exercised the amount of bringing $X.X strong company of stock, a in by million, XXXX in the date received total outstanding longstanding purchase to investor aggregate

I strengthened from funding further some Belgium. with to our additional the balance quarter delighted fund nondilutive sheet that am we also in announce SOFINEX to end subsequent

able to proud cash really to of work also burn million $X.X are all done the right per with XXXX We have quarter. consistent our be of throughout quarterly approximately

regards position believe key at We and with milestones. sound continue a our very achieve XXXX to are to we manage to XXXX that cash financial runway carefully the and

effective were we of include subjects approximately total University study study Computed large This that once years. $XXX,XXX quarter, third worldwide. trials delighted yet first large-scale Low-Dose scans at Tomography VolitionRx's National Taiwan lung payable XXXX over cost commenced conducting to more demonstrates our the During commitment which the cancer a will two receiving cost

proof-of-concept have next are Shanghai initial lung XXXX and the platform half release Co. to cancer executed key of Fosun that in patients new to our the also the the Science introduce March with larger in XXX remainder the much contract recent Long will be a Ltd excited We to this end year. Medical were data to We in by expect China. to of cohort repeated relating hopeful and first preliminary results

our Executive data, on from samples we colorectal month much made I Fosun Officer earlier. the the Jasmine lung our a product working and am cancer traveling the mentioned started very and out [indiscernible] discussions I Chief promising VolitionRx's initially Dr. Nu.Q using that to study on parties collect Singapore together the are later assays platform Based to recent East already Kway, with expanded team. proof-of-concept continuing Far are forward have and looking new to with this

based operations on welcome further and Executive Vet subsidiary, Dewsbury team. Nu.Q products the the completed LLC have to driver and to new quarter this Development happy Veterinary majority Nathan the revenue Texas formation of of its commenced our were focus will Vet company. commercialization owned Diagnostic for helped VolitionRx and and early Officer, Chief our development We VolitionRx

to moving received Dr. the On the and Associate the Texas meetings Professor The market our in the things with at largest are Texas, Houston. world. of on also Wilson-Robles, product at Vet. potential in fast. of VCS important research a data October, all of Cancer to Conference one month pre-analytical quarter generated much the delighted to we Conference presentation oncology Heather interest was development in the execute Veterinary end, University Annual new were Veterinary subsequent The the veterinary collaborate and contract presented Last in front, Nu.Q A&M Nu.Q well the Society and Vet A&M is in Veterinary,

and impressed working available incredibly bring facility VolitionRx with our A Members have with to the sign And A&M Also market. is of say Texas be trip memorializing and of market. other veterinary Vet the the in A&M we the the I will to contract, team Executive with Texas products between video are collaboration Board the in October, capturing some to we Nu.Q Team, website. along both I visited on and to the

VolitionRx's On steadily. portfolio This is Scientific is of yet thank of or aspects for work the Micallef, And our patents in would outstanding key Dr. market. technology technologies with our under other his these intellectual development in I writing like patents. the various Jake property protects Officer of all Nu.Q many that granted front, Chief to available differentiator another growing worldwide

X and patents the X European States, in families have We tests further granted the granted XX worldwide. granted Union, related to in XX a our patent patents with United diagnostic patents

field We our intend epigenetics for pioneering the the [ph] to of U.S. in patents our Additionally, also to medical work continue patent applications portfolio product technologies and proprietary in applications. the have in applications through European covers developments. our This Neucleosomics Union. XX apply of the will the future pending continue development such in XX name for we patent of and subsidiaries veterinary

with at exclusivity in coverage the United strategy market Our strategy believe We countries. provide Europe our underlying product gain patents to our the is in protect including least technologies each other protection patents technologies through and that products States broad XXXX. and and the on for should

And future with trials studies before large return a development of moving as finally, early to assay and on with sized in lung automated so program scale has well, cancer gone an XXXX, milestones, to our medium platform our on flagship can now trials. colorectal range assays we the starting to

report to year. data the the next first this expect half first We in of of

on scientific to We publication clinical underway coming one conferences these in we abstract the are months. and for least trials work for for upcoming expect at and the stepping submissions preparations paper up submit are

revolutionize we studies, several cancer that which the is In our is test hope for very year. much be addition, simple, cost we first and realizing will to Nu.Q data effective later use, been the we proof-of-concept tests easy truly from have help cancer for need universal this way on can worldwide. diagnosed The working

our about are We the and to March. collaboration work the forward a commencement successful and Fosun studies with to China look excited Long of completing in

hopeful forward the beginning launch our of immunoassay next marking begun the and of registration also development CE upcoming on to Asian Europe coming picking first Vet pace and we have is triage and data We we'll The Nu.Q this provide products in and at key our announce of markets for months. final product an to in the colorectal quarter present are for cancer indeed lung XXXX, in and and up in the in the process the details in first and half next to of throughout Capture both half Nu.Q first for clinical the look in second of announcing demonstrating approach sequencing hopefully Nu.Q conferences step year. utility first our We next Vet aim year. further

key and cash data week our Our throughout both Finance beyond in solid whole animals, data this clinical our in Board including who first position milestones, team, by just with a aim excited to the range China in Nu.Q on our Advisory Nu.Q's represents. Capture. several met We including ability are from to preliminary report last XXXX to opportunities and addition studies of detect cancers including humans incredibly

animal be We reputations are human VolitionRx world, early whom mission of diagnosis our advancing it to the from science exploiting and our epigenetics. is around since delighted and aim and these heart our health. coming working the of all and share been epigenetics collaborators the cancer has of founding platform on at Nu.Q an have very to company improving focused diseases. other advances our with epigenetics is with in fruition in This and of outstanding

to with field. strong the last significant work not this full believe decade it epigenetics expansive be VolitionRx of IP an DNA, position portfolio puts extremely Remember, that the is in is in it We chromosome important. our player is in

to supply We also in-house. bringing strengthen them for by further chain intend components our key

extremely are holds what we VolitionRx. have look forward accomplishments the future achieved proud the far and We thus of for to

platform. the along the indeed the our with year of sharing to of board optimized with coming I, whole rest studies look over and key the results company forward

most XXXX exciting be our We to yes. expect year

take I joining busy the appreciate to given very for it, your call cold we are earnings the Thanks season, question. today. Operator? much happy

Operator

[Operator question with Please your Group. Instructions] line from of Maxim Jason comes McCarthy Our proceed question. the with first

Jason McCarthy

the Hey taking guys, and thanks on for the progress. question congrats

Cameron Reynolds

Jason you, Thank

Jason McCarthy

have the September to how the So data you from program? you you milestone specifically Capture help back hit you contextualize could Nu.Q the on like previous defers I'd if see that in and

Cameron Reynolds

Yes, if through call. depth, with of for Chief go you here, talk to and Scientist it to purpose but in our much absolutely, want more is the this

structure proved them one extremely benefit March [indiscernible] just worked Day temple the the We of Plus we've of around we on good one out, in returns, beads. back we've which well, that York. announced which pull now is the most that's and background So to Markets which the can with the we Capital another XX% fantastic. work been started could of the all and pull capture magnetic was nucleosomes so New we then assay we doing the between process XX% of out time what in

said but to Nature. to payers few also DNA we time also markets what And are looking shown been has at other a be nucleosomes less DNA than from likely origins, if not cancer that get With was also too to and tumor base nucleosomes. in do, do could papers with much concentrate we're technical, in it we including see sections than ones of XXX more more of around the from

the marker So concentration and verus without the nucleosomes we so from that, which pulls a lung out massive [indiscernible] it does tumor. of do do

and was breakthough that so very incredibly Now, the team big a is happy. very,

so up on or to it like now ahead I that finish around we're a the assays markets and is pulling dampness a including what as to starting final is, of to out can but working what the use do. now done So on doing see we sequencing of there's range the there looks steps is spectrometry wide to range and can our almost of some add far there we three structures, concentration that we've very think discrimination, but mass

like out, methylation So, do We are other to [ph] no or to or pull range them cancer. hopefully or can pull of in markets then things depending structures on need and that preferentially preferential preparing many also out one and using. concentrating them be lease

as [indiscernible] scientific the for world on extremely good through I advisory us to of I it a keen range think is far the but, was wide So incredibly revenue think level are I and like and changing companies. last as week revenue other very, And I of potential meeting starting on Not said this. board level a potentially only source goes, very but a help licensing. think

should data to So include would the first around hope of or and we in sequencing is have picking next Morgan time we next really which JP it up. the year part so data

clear? Was that

Jason McCarthy

much. Yes, very

that Nu.Q have the on of more So I be thank you to the Capture specificity test. because used actually increase you. it do the one can mention

this then would that generation for would I'd more So to, a be will the it separately integrated like validated used existing an as panels? something this into second or and step additional test be would be be,

Cameron Reynolds

out because Yes, step the use use would pull magnet, where it's we the obvious, it you a are very all, that's that how then by you magnet at good as nucleosomes, thorough and what them, pulling really working it not use it reason the preferentially nucleosomes be we're magnetic nucleosomes. have so is but question. noise But That's haven’t but out blade something, since been either taking a first of would is it, to a, mainly then, the obvious tumor, the guided, from you integrated. is once we've background or out it, a a what

this, right So on again, you that he has to couldn’t means noise share better you which like data but believe we would a would haven’t accuracy. signal go lead obviously been give his which clinical know sleep better to

would, I this do of is This of until of is It low so our with start, is We to thinking. it's decisions. make assay the it is step. so a a very the first all won't all step. analogous work we've another cost, now. this So very a few we're could just, made It part an final again simple is kind dollars public doing to

then there're how That's nucleosomes either of doing So to from background the it we the systems right but out cancer kind clear preference and or process year the the we but in and be doing at. the which we first thinking, first also and us numbers around ways assays. pull run the But can to definitely short. can that a other the long and step have up from the of definitely concentrate would helps new we looked to the will have half we're what

but will exact come through numbers soon. very So the it's looking good

Jason McCarthy

mean with more because a A&M. I just on presented work, Thanks And subsidiary just then the you've Nu.Q preclinical the one – Vet you actually on perfect. new established

what up does So end steps for are that how Vet the market? Nu.Q getting to next and then

Cameron Reynolds

question are first we teams the are – do – all market really these with from we market very steps to the had humans are come and we homes nuclear actually novel just very through going same call results the zones. so to actually that similar because we now Texas have Yeah good human we it getting similar into the

like obviously things potentials as So in animals there but are you well. capture the

But back in the and steps for you one the that. cancer very And I think to samples similar exciting very breeds the also the cancers you're want world doing like relapse market, next now. the blood a humans the which high am there the for so diagnosed things the market if frontline two risk, of One lymphoma. screening, it's non-Hodgkin’s major sure like like cancers, make common I are I dog so in human collecting not getting or been guess to you've trials in in

– we are kits a the we well. a capture, animals setting to in shipping on grade markets So see bio-analyzer they the they they them they'll be used so up as production are are And continuing like use can be areas. run lab other ours be can quality and in to more and

speed greatly should that the process. So up

use the only in to important two is two their lab. main as ways our far goes, market, there product ways kits as product So the

an blood of it facility there We Texas. very in absolutely amazing it better team lot humans facility it's where not are a a and wide from fantastic. in human, world, day. get has it's a The lab treated They lot good hundreds hundreds range and remarkable coming was had clear tour was than been of quite a their not samples it's own they lab, the areas their clear of model, a but run

of their lab. their And run some they tests in

to that sensitivity are year, which is human are to in to first the aim which the way facility the kits have would hospital. the a middle year, our hospital is and clear going So end next And of one underground world based next lab be the in best the they their below on assays. use we

it So very could be quick.

States that the And [indiscernible] roughly actually is the running well. that's clear a hospitals the is United kits vet potentially still the labs sell that. the do comfortable months would in - after ones kits be and there a then what which in as USDA, running markets will about is those up big nine fantastic XX we other happy from around license or hospitals the to you and vet it big in [indiscernible] he and market the smaller

So year we're next hopeful start that's something then production and a off USDA to have XXXX.

Jason McCarthy

much. you right, very All thank

Cameron Reynolds

you, thanks for Thank time. your

Operator

you. Thank

Please from comes the Breidenbach question proceed question. Oppenheimer. next line Mark with your of Our with

Mark Breidenbach

question. Hey, the guys, thanks for taking

Cameron Reynolds

Hi Mark.

Mark Breidenbach

of process So testing. I product all, Triage you lung Cameron, is but the sort talked if Triage Triage the product I too I for now you used first? in what these needs could colorectal your that have you quite of wondering underway and timelines you sort Where for colorectal mentioned and of maybe think know lung about to and of don't products, both product Triage be that marking much test can fit where to point talk in countries in think the heard nationalize Scandinavian was more before. in through would it We completing I process expect bit that a CE lung. of product happen us and before when a the we've would first in, specifically about launches walk also

Cameron Reynolds

States familiar absolutely screening used Yes, dose probably in commonly in which scan, it’s where It's you're actually also low high sensitive. quite a is we're trial. running a used CT the the is cancer, with, for risk United Taiwan, so, there currently lung only people which for

of a specificity, good there a means in sensitivity So out number very test positives. the it's there but good but up cancers, picking horrible for huge [indiscernible] it's which is false

unless being biopsy want And is the lung, something the you're really obvious going problem is with for in where not needle risks. the that stuck can a is step on, a you certain the which be next

would into So the world we about to partners we've talked where around that. fit

So what looking they're for.

some So kit smoker, on for the seven you're the probably you reason good it's a current have lumps chest if is sensitivity your year old

File X

lumps chest find if cancer on lump. we some a it's then your and will

cancer, have even you don't But the probably lumps, smoker. if other an problem you're if is older you have

lumps, So including else. everything the it picks up all

they problems is done that hoping If are do problems there So able the are hope currently other. we two – the one is the the problems to with – false dose be what low positives. two it's solve CT to tests the or problems with specificity, meaning

low you who biopsy, risk Nu.Q have extremely the So first, to the and those show the lung Triage dose have to have CT second for then people really make high cancer but is scan having sure you you're test it's secondary, if low it's risk a – If before. on you you could also biopsy increased lung have monitoring do which before specificity. that so, also very more same don't – a it's

is problem second colorectal compliance screening in The about compliances [indiscernible]

for it's considered risky of scan because lot CT like low don't little who scans. and people a want bit a dose There's radiation having people don't

other may drive talk want groups compliance. we to first So to to who do with

So you well the say, test. go Triage a Nu.Q be test for used dose have to and then CT to low data need afterwards look as your really you and in the could scan

So well I very into pathway. fits think it that

format. good are the looking on we the Again, have manual assays to we're now very not finished which

things feedback and analytically colorectal screening on of ad March, assays. very, we’ll whole So are frontline a doing base. in we better like it's a this in is working was very them from for those doing which very assays because of one it's manual we're range platform released – two we're in But so large all format, or the platforms. panel two we The accurate, reproducible, well you've the why do all much seeing data seen

we perfect to Triage. low Taiwanese the so have includes would – CT see trial scans all people the So for dose there? expect data had that's have when So from who

obviously Some have which, which some nodules. other have of cancer, benign

which better juice terms have a like there's all. for And clean at no lung, some of

or either be it potentially used be positive be we So and good we'll for on negative seeing collection. to expect

You biopsy do don't a or as a need or Triage. negative positive you

we've Taiwan can lung based in fantastic we're kind in has in them come that We that, results the tell and trials So probably you about very pack. hope excited the to as U.S. through really We're doing we had this of start some on and China, we data. announced.

So in clicking colorectal very in very, Taiwan. timing wise, well the lung they are and the

And those run the the samples chunk or which because CE we in half, to of the the end near first the pipe second are to first hopefully Triage for run then of it's And the early marking. we'd the quarter. purpose, format, expect have the first assays big that we'd

place you've two once if there in sure So so for not purpose, others one CE much reasons is the marked you this. to it’s so for quicker CE marks remember

run very marking purpose made main to place lab make the be in can But the the properly anywhere. reproducible is sure of CE well any robust, controls are run, they and

been are use one want lung for also the have CE just well made. once means properly dog purpose of but we obviously the different dogs kits mark products, the incidentally for take to it care same it We these as we’ll the markets our animals, CE market. humans from not for So, of cancer

then tremendous the already in been that dog all for background perfect kits them inside the done. you different markets, from works product. the samples, And other run CE all work you then market or purpose, the and when the absolutely but And mark just they're have for

And in a So real it's lung. areas. we the from momentum first all those the have we’re dose still getting

Mark Breidenbach

If I for just second? interrupt a can

Cameron Reynolds

Yeah sure.

Mark Breidenbach

not future products be in pursuing be the that is you're selling? the exactly to you're that Triage is market some won't that the go launched have maybe now necessarily and right marks now CE the stuff different at marketing point CE products correct you'll Then what that you'll eventually are

Cameron Reynolds

mark be Yes, one two doing or then areas, well with CE bigger and trials and those assays. no you’ll we'll

in CE for we X,XXX going mark and on Taiwan that of the CE sell including means bigger to doing for different samples, trial which mark and a to be bigger can purpose for So in that cancer. you few hundred do trials, range we're can X,XXXone a whatever lung this cancers you have it obviously a

platform. So it's a

So products it and in do to use, becomes But once for colorectal lung in much do easier yes, trial, animal marked the animal one and multiple you market in those expect to launch areas. the even marks CE CE these using we side

X File

will animal so doing But lot that's marks. something using CE the of. which a these side be yeah,

Mark Breidenbach

we last colorectal the estimate from the and for ballpark scale studies call let's for just can and away initiating flagship lung one in in you follow-up from how larger maybe a them – studies me, us give Okay, far asymptomatic are patient?

Cameron Reynolds

we very, need the And has Yeah very well. them they're going on which range well. so, as new said a of will very kept collecting I format,

data year. we So lot and the flagship size next and assay start give first the a platform first year, trials. base enough have but very half will we'll half meaningful second starting small year, as products in next – second of late accuracy a but just have big that’s of but trials the second in half the in the quarter on start first in of on still on medium or to of running trials The this flagship the medium very asymptomatic, through month the expect then next to them we to of good the the launch year, us next

Mark Breidenbach

you for thank it, the questions. taking Got

Cameron Reynolds

you Thank anytime.

Operator

Thank you.

The Benchmark question comes from Jackson Bruce line with Please proceed with question. next Our of your Company.

Bruce Jackson

for you thank Hi taking questions. the

Cameron Reynolds

Hi Bruce.

Bruce Jackson

give bond first? be of which and from endometriosis the to going releases us study cancers are with upcoming data little could in coming publications maybe reported and So a and from for a the this is the feel study the bit

Cameron Reynolds

our also of We’ve range lung actually a endometriosis. in will you there cancer some work work lot as dog Yes in as a a going but about also know excited We’ve to in it background as another in colorectal. month is will few be we're learnt be lung cancer that of public [indiscernible] announcing be we've from done work next of weeks cancers very wide we're one which well. done

these on best with think best the actually I on work assays and had lung been had the results first we've plate the we've So the very last format.

of lot names And well all work will preanalytics are with very as which doing also on also as be work lung. to which a non-cancer. done research We've is publishable. also be we're capture, contract that's So a also published, all the expected

work – really we're the to reasons. on group So group and these only first to

to of in with recombinant there trove be an the the the through those are going to way plasma. treasure serum be publishing absolute on our assays. what's All and in We've all So is best things antibodies will run stuff information published. gone

we and start Jake's finished been to been now. furiously. to writing expect all it So you We – well has that process know as be patents wanted

last bunch them the months. done of We've another in few

part now. believe problem the diagnostics. of is So confident we're in the a answer the to absolutely a We huge very position epigenetics

improving a I think cancers cancer. non in We're it. working we're bits and the worked range time confident start background time for very still other and the of we've I of work now all on publishing, solutions. the think is and But

publications have when be to will but a come we'll details exact The we now out, talk about start huge amount soon.

Bruce Jackson

the revenue? revenue, then, this Okay, think your quarter I to of quarter, research great. with right this some regard And revenue is first

Cameron Reynolds

XX how very about base all sold our it a our much it’s technology. And was a so so kits kits we’re research started. we mixture. We we're with very that contract happy using so did Yes

carting and great – yes is everything really well. So of starting

Bruce Jackson

grow you one terms generating And something that this stream, question then from second is begin to revenue revenue research, like clinical when of And revenue do think of continuing to going you to going be you're the is then part products? do interment. in think can the it's of generate

Cameron Reynolds

lot as and done question obviously, of given to good as revenue best possible. get it Yeah, something to thought quickly drive how and we've a

So last give the looked and of were burst, time launched happy got with for since those of through. a we're I'll was very revenue bit time first contract. Yes, both run the tickets we first quarter, a we we've done just a the there quick

be a think it's think to I year. So of next I through last from bit going grow steadily it'll a but burst quarter,

can to – solidly and think two listing just of I build expect be have areas from, because So will the from the contract that research. want, types through get year will or the one is we lumpy and quarters a some but bit revenue this some we only we research contracts

only to all areas. epigenetics market. And really taking we're has I on the in range and is of have intend wide a off these we So kits company the really who as said,

samples become and that do run We I to contract the when people but don't research will to more want And can their we more do lab. what in want think do it

XX File

source probably side assays big up and to And really say be to half. first obviously, to the will I assays Triage get have. revenue the a have in products, colorectal perfect these the the that we uses. we next also next the as we for can taken think lung a do time from tough that marking long charge The of is revenue and we’ll CE best also collect has And of picked working trials. the is it's the lot of sort results

by now – to few next expect I'm lot a you the China said in revenue we have opportunities And of I’d in launch end space weeks. So the in a year. from veterinary do of as licensing

a give capture. next possibility more updates there also in some think of I you certainly does the from are updates happen I'll licensing year Chinese and that is market. if

absolutely prospects enraptured Nu.Q As whole it I really claim I with can’t how transform the and industry. said, the Capture could for

Europe and strongly we on data quarter potential I discussions revenue perfecting big that's, big getting Europe that trials the think begin and the Asia. the haven't think big very from and the mentioned think will half, year. U.S., Jason in finals. the asymptomatic we're because But now for But the first still I in So – next I in on we the

much the to I but think to earliest likely more be more be are in at of XXXX. likely next the end year, much

take the year, next ready have would we as research to absolutely to range think, really We then on is So an feels we that’s it potential kick And expect of but think different of a in thought platform take assays see I coming year. going expect use wouldn't dozen a next really sources big different its demand revenue it in conditions. And off And we kick large to at because pent have until I up have lift. for off, least really will begins should the epigenetics XXXX. a huge cancers, I do through revenue, but now.

Bruce Jackson

Right.

Cameron Reynolds

mobile afterwards if the want you If free get I through models you need. like three can all the can you'd talk to

Bruce Jackson

that great. Thanks will be great, will right. Thank much. be you That very

Cameron Reynolds

Bruce. Thanks

Operator

you. Thank

Edison Research. the Please Our proceed from next comes question question. of with line your Peciulis Jonas with

Jonas Peciulis

like sounds Yes quite had this. so you for hi congratulations quarter busy a

the I mean the of some You you to also like all But or vet product talked – those how university I side of the commercial need what then lapsed. to – high just seems setup – why how sounds have to thinking reps and like activities. with about they things been so or that the like increase they Nu.Q about product of will do about and will kind some capacity the are marketing I about timelines distribute tell are you mean mean it and increase sure how, talk what awareness risk? promotional you practitioners capabilities will they the be the kind

Cameron Reynolds

so may fronts. it and coming through in how question happy be couldn’t things its with be I really really Yes has – many thanks going a yes been busy are

which And to lab would look other launch be big vet licensing product the need not the reps. in so yes sales would to So equipment the the we broaden market. to that labs, does in clear imagine –

in [indiscernible] We are sales specialist area. on the taking a is who

of not tell are together with but it I that universities, you through. we the reps. sales in human set dog numbers for is a go don't in [indiscernible] simple really tests the for everything vet is space to And then products change thesis Being there currently up but don't large current out whole putting of want reps, a and a roll is product price market and He the we system I think public, we I what else. through and through us plans from see can made how been has this is

to intend intend that's everything kept forces the to really don't teams. don't large sales wheel or we have reinvent low cost. And we We how

Now if We do it. do don't don't we need to it.

a So them. situation the to where lot sales space. to But force key no We market for to and we going need there's process a who people in the absolutely lot need we're human people did of see the I one. don’t any need few sell a

is base move a thing well the also in vet the being And on machines hospitals, also good that's magnetic as can format centralized the hospitals. the vet also we the big plate the from market for to

same said So cancer it very, human complimentary think space human and And the tackle it's I the in I space. very we'll a tackle to yes,

XX File

tackle in both cancer ends way. of same leash to the the

the vet I think our model market. to is very transferable

Jonas Peciulis

in working the you China, tell that cancer lung ongoing. in have going collaboration disclaim about one cancer so I'm the and correct, files little mentioned And you a started press it? as international release colorectal Can bit the if you more to you No I close in so well.

Cameron Reynolds

we're I've the absolutely They their also I Yes, have question so we results impressed and and think Lumina. with been do machine what what about. the

manual use initiated can they as so colorectal Yeah, going on was uses they're so with work. what Lumina the happy we’re getting beads, or So trial plates the that they've well. very to

point, data either expect have because soon. a data, but to the it's some from colorectal that mentioned could up data lung release I've on we see or as the gifts they I that So coming obviously that soon. within when their

our I many size given out as But think on few would large I'm to to of and and of roll weeks, I want charge the can we a continue Nu.Q those a we market see the how I And actually going in China. with countries. opportunity size am discussions licensing two best of something large weeks, very opportunity, the products. where our China a so in range not really launch in

payments for So be with mixture of deals royalties. milestone and I’ll looking the

which in label a continue best on the and platform China is what to developing revolutionizing Chinese do selling we'll group. really and we with And epigenetics

facing be that's going. to happy going but continue we that's I'm if very the discussions, how hopefully So

Jonas Peciulis

I indication cancer collaboration more international would make in as potential sense that these going All right wouldn’t be in terms are you data there well. cancer or what is so of the there will lung the like colorectal there probably know to you [indiscernible] important I two But see focusing with cancers? and manipulation But for answering terms just opportunity of in from yeah, be know took lead was way. probably the be to would

Cameron Reynolds

we like things [indiscernible] are lot head a have cancers. neck populations, different cancers, the all and different slightly more some human and a beings cancers and But, of other have we're there. in Chinese commonality common so The

India I develop relationships licensed through or perfect China in one and areas relationship groups that it a Asia relationship if to would or products, like range then the working, in of be two think someone products a with well. wide other or get going

very and if finish all I so did, every choice to they're the And the as well, could there. far. working yet are But well, be I other in options. not good. we to discussions a cancer that'd with think the be in as that trial very massive to, China, is But It's going but range would us lead be like cancer launched indication continuing going think work our But seem in is colorectal very of which that so be working forward to may and rise China, if We soon. them. I know, I’m of cancers look any in those there's our there could lung assays we on in work interested

Jonas Peciulis

thank you. Okay,

[indiscernible]. So

Cameron Reynolds

Jonas. Thanks

Operator

back answer final concludes comments. for I'll Thank to and Reynolds any gentlemen, session. the that Mr. turn you, question floor our and ladies

Cameron Reynolds

big truly and a we're be for everyone have time I And you taking so a Also thanks year there. mean our XXXX going think fantastic going busy know of over short you, Volition. interest. Thank to be I months team would you there. two we're all to Morgan be at for to those I That's it's JP to for going a

can track of doing So your coming all and time. updates Thanks again hopefully for you a up. we're keep lot what have we'll

Operator

concludes today’s This Thank you. teleconference.

You at participation. lines for disconnect you Thank time. your your this

VolitionRx Limited (VNRX) 13 Nov 192019 Q3 Earnings call transcript